Zydus Lifesciences
BSE 532321 · ISIN INE010B01027
16 stories, newest first.
- Zydus Lifesciences Q2 FY27 results on Nov 4, 2026; post-results earnings call same day at 3:30 p.m. IST
- Zylidac Bio and Prolific Machines partner to scale Prolific's light-controlled biologics platform to GMP production
- Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity
- Board meeting on November 4, 2026 to approve unaudited results for quarter and half year ended September 30, 2026
- NSRAL assigns overall ESG rating of 71; company placed in 'leader' category for financial year 2026
- Zydus-Sunshine JV signs agreement with Board of Investment, Sri Lanka to set up pharma facility
- USFDA inspection at Moraiya plant concludes with 5 observations
- USFDA accepts for review FYB206, a proposed Keytruda biosimilar; decision could come in Q3 2027
- Zydus Lifesciences got positive phase 3 trial response for a liver disease drug, under US FDA review
- Post Hoc Analysis of Phase 3 EPICS-III Trial Shows Greater Biochemical Response With Saroglitazar vs Placebo in PBC
- First-to-market generic of Adempas (Riociguat Tablets) launched in the U.S
- Closing date of 50:50 joint venture extended; completion now expected by December 2026
- Ruchit Jain of Motilal Oswal recommended buying Zydus Lifesciences citing pharma sector relative strength
- USFDA cGMP inspection at SEZ II, Ahmedabad plant closes with one observation
- Chandan Tapare recommended buying Zydus Lifesciences on dips
- USFDA inspection of pharmacovigilance system at New Jersey office closes with nil observations
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.